Movement Alert｜Luye Pharma Rises 5.91% in Regular Trading, UBS Increases Stake Amid Innovative Drug Sector Rebound

Market Focus07-03

On July 3, Luye Pharma rose 5.91% in regular trading, trading at HK$1.96/share, with turnover of HK$79.33 million.

On the news front, according to HKEX disclosure filings, UBS Group AG increased its holdings in Luye Pharma by approximately 33.98 million shares on June 22, raising its long position from 13.22% to 14.07%, with latest holdings of approximately 562 million shares. This marks a continued buildup by UBS, which had previously added 13.95 million shares at approximately HK$2.85 per share in early April.

Simultaneously, the innovative drug sector is staging a broad recovery following a significant prior pullback. Sector peers Hansoh Pharma gained 7.47%, CSPC Pharma rose 4.9%, and Sino Biopharm added 2.81%, indicating clear capital rotation back into the sector. Luye Pharma's core pipeline drug LY03015 previously delivered positive Phase 2 clinical data in China, with the highest-dose group achieving a 76.5% response rate, nearly double historical first-line drug data, and the company plans to advance into Phase 3 trials in both China and the U.S.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112515279?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112515279","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Luye Pharma Rises 5.91% in Regular Trading, UBS Increases Stake Amid Innovative Drug Sector Rebound","media":"Market Focus","content":"<p><p>On July 3, Luye Pharma rose 5.91% in regular trading, trading at HK$1.96/share, with turnover of HK$79.33 million.</p><p>On the news front, according to HKEX disclosure filings, UBS Group AG increased its holdings in Luye Pharma by approximately 33.98 million shares on June 22, raising its long position from 13.22% to 14.07%, with latest holdings of approximately 562 million shares. This marks a continued buildup by UBS, which had previously added 13.95 million shares at approximately HK$2.85 per share in early April.</p><p>Simultaneously, the innovative drug sector is staging a broad recovery following a significant prior pullback. Sector peers Hansoh Pharma gained 7.47%, CSPC Pharma rose 4.9%, and Sino Biopharm added 2.81%, indicating clear capital rotation back into the sector. Luye Pharma's core pipeline drug LY03015 previously delivered positive Phase 2 clinical data in China, with the highest-dose group achieving a 76.5% response rate, nearly double historical first-line drug data, and the company plans to advance into Phase 3 trials in both China and the U.S.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Luye Pharma Rises 5.91% in Regular Trading, UBS Increases Stake Amid Innovative Drug Sector Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Luye Pharma Rises 5.91% in Regular Trading, UBS Increases Stake Amid Innovative Drug Sector Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-03 10:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 3, Luye Pharma rose 5.91% in regular trading, trading at HK$1.96/share, with turnover of HK$79.33 million.</p><p>On the news front, according to HKEX disclosure filings, UBS Group AG increased its holdings in Luye Pharma by approximately 33.98 million shares on June 22, raising its long position from 13.22% to 14.07%, with latest holdings of approximately 562 million shares. This marks a continued buildup by UBS, which had previously added 13.95 million shares at approximately HK$2.85 per share in early April.</p><p>Simultaneously, the innovative drug sector is staging a broad recovery following a significant prior pullback. Sector peers Hansoh Pharma gained 7.47%, CSPC Pharma rose 4.9%, and Sino Biopharm added 2.81%, indicating clear capital rotation back into the sector. Luye Pharma's core pipeline drug LY03015 previously delivered positive Phase 2 clinical data in China, with the highest-dose group achieving a 76.5% response rate, nearly double historical first-line drug data, and the company plans to advance into Phase 3 trials in both China and the U.S.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02186","symbol_name":"绿叶制药","start_time":0,"source_url":"","article_id":"1112515279","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112515279","pubTimestamp":1783044397,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 3, Luye Pharma rose 5.91% in regular trading, trading at HK$1.96/share, with turnover of HK$79.33 million.On the news front, according to HKEX disclosure filings, UBS Group AG increased its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02186":"绿叶制药"},"translate_title":"动向提示|绿叶制药常规交易涨5.91%瑞银增持创新药板块反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":1},"content_text":"On July 3, Luye Pharma rose 5.91% in regular trading, trading at HK$1.96/share, with turnover of HK$79.33 million.On the news front, according to HKEX disclosure filings, UBS Group AG increased its holdings in Luye Pharma by approximately 33.98 million shares on June 22, raising its long position from 13.22% to 14.07%, with latest holdings of approximately 562 million shares. This marks a continued buildup by UBS, which had previously added 13.95 million shares at approximately HK$2.85 per share in early April.Simultaneously, the innovative drug sector is staging a broad recovery following a significant prior pullback. Sector peers Hansoh Pharma gained 7.47%, CSPC Pharma rose 4.9%, and Sino Biopharm added 2.81%, indicating clear capital rotation back into the sector. Luye Pharma's core pipeline drug LY03015 previously delivered positive Phase 2 clinical data in China, with the highest-dose group achieving a 76.5% response rate, nearly double historical first-line drug data, and the company plans to advance into Phase 3 trials in both China and the U.S.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112515279","isCrawlerRequest":true}